Likewise, maraviroc, a CCR5 antagonist, significantly reduces the HIV-induced AD-like brain pathologies, including Aβ deposition and tau hyperphosphorylation, which may result from the increased transendothelial Aβ transport via LRP1 pathways (Bhargavan et al., 2021). Here, LRP1 is linked to Alzheimer disease.